Table 2.
Summary of baseline characteristics of patients in validation cohort
| Characteristic | Value | Characteristic | Value |
|---|---|---|---|
| Age (y) | 60.0 ± 13.0 | Extent of disease | |
| Sex | Locally advanced | 14 (46.7%) | |
| Male | 22 (73.3%) | N1 lymph node metastasis | 11 (36.7%) |
| Female | 8 (26.7%) | N2 or extrahepatic distant metastasis | 5 (16.7%) |
| HBV infection | Macroscopic growth patterns | ||
| No | 23 (76.7%) | PI | 15 (50.0%) |
| Yes | 7 (23.3%) | MF | 15 (50.0%) |
| Child-Pugh class | CEA (ng/mL) | ||
| A | 13 (43.3%) | <10 ng/mL | 27 (90.0%) |
| B | 7 (56.7%) | >10 ng/mL | 3 (10.0%) |
| ALBI grade | CA19-9 (U/mL) | ||
| 1 | 7 (23.3%) | <200 U/mL | 9 (30.0%) |
| 2 | 22 (73.3%) | >200 U/mL | 21 (70.0%) |
| 3 | 1 (3.3%) | ECOG performance status | |
| Total bilirubin (μmol/L) | 0 | 15 (50.0%) | |
| Median | 61.3 | 1 | 13 (43.3%) |
| Range | 14.9–100 | 2 | 2 (6.7%) |
| Albumin (g/L) | HAIC cycles | ||
| Median | 41.31 | Median | 4.87 |
| Range | 32.6–49.7 | Range | 2–6 |
| Survival (months) | |||
| mOS | 16.4 (10.77–22.2) | ||
| mPFS | 11.2 (8.55–13.9) |
PI: periductal infiltrating; MF: mass-forming; CEA: carcinoembryonic antigen; HBV: hepatitis B virus; CA19-9: carbohydrate antigen 19-9; ALBI: albumin-bilirubin; ECOG: Eastern Cooperative Oncology Group; HAIC: hepatic arterial infusion chemotherapy; mOS: median overall survival; mPFS: median progression-free survival.